Knight to present at the 2022 RBC Capital Markets Global Healthcare Conference in New York

Therapeutic Knight

MONTREAL, May 11, 2022 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Pan American (ex-US) specialty pharmaceutical company, today announced that Samira Sakhia, President and Chief Executive Officer, is set to participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Wednesday, May 18, 2022 at 8:30 a.m. ET at the InterContinental New York Barclay Hotel in New York City.

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight owns Biotoscana Investments SA, a pan-Latin American specialty pharmaceutical company. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc. shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s website at or

Forward-looking statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. believes that the assumptions on which these forward-looking statements are based are reasonable at the time they were made, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be erroneous. Factors and risks that could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and Knight Therapeutics Inc.’s Annual Information Form for the fiscal year ended December 31, 2021, as filed on Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information or future events, except as required by law.